Business Wire

TSUNO-GROUP

Share
Tsuno Group successfully developed and applied for a patent for a stable formulation with a high dosage of FERULIC ACID, a rare natural plant-derived ingredient having the function of absorbing UV.

Tsuno Group Co., Ltd., headquartered in Katsuragi-cho, Ito-gun, Wakayama, and led by President: Fumi Tsuno and Matsumoto Trading Co., Ltd., headquartered in Chuo-ku, Tokyo, with CEO Shunsuke Matsumoto have successfully developed a new sunscreen formulation with Ferulic Acid. Ferulic Acid is a rare natural plant-derived UV absorber that has been difficult in stability and solubility at the high concentrations of ferulic acid.

For ferulic acid

Tsuno Group was the first in the world to successfully produce large amounts of ferulic acid, a polyphenol, from rice bran. Ferulic acid possesses strong antioxidant properties and has been recognized for its potential to prevent Alzheimer's disease, diabetes mellitus, and high cholesterol. It can also be used as a raw material for producing natural vanillin, a vanilla flavoring. In cosmetics, it inhibits melanin production by blocking tyrosinase activity and has anti-inflammatory, antimicrobial, and antioxidant properties. Therefore, it has been used as an active ingredient in a variety of cosmetic products.

“We, as a leading company in rice & bran chemistry in the world, have been developing a number of functional products with tremendous efforts through accumulating technologies, have also researched their safe levels and effects to be well accepted in pharma, food, feed and cosmetic industries. Now we have launched a technology of using ferulic acid from rice bran as a natural antioxidant and UV absorber, which is the first innovation ever in the world. We are confident that you shall discover this product as unique and impactful to contribute not only to the human health and beauty but the circular economy for the world.” —— Fumi Tsuno, President of Tsuno Group Co., Ltd.

UV absorption effect of ferulic acid

Ethylhexyl methoxycinnamate (EHMC), a petrochemical UV filter, is most widely used in sunscreen applications. However, recent studies have shown its negative impact on the aquatic environment, including coral bleaching. Ferulic acid, a naturally derived sunscreen ingredient from rice, absorbs UV rays in a similar range of the spectrum as octyl methoxycinnamate (OMC). This promising characteristic makes it a potential eco-friendly alternative to EHMC. Amidst growing global concerns about environmental sustainability, ferulic acid's potential as a natural and effective sunscreen ingredient is likely to gain increased recognition. It holds significant potential for application in a wide range of cosmetic products throughout Japan.

Development of high stability formulation of UV-care products with high concentration of Ferulic Acid

Gaining recognition for its UV-absorbing properties, ferulic acid, a rare natural plant-derived ingredient, presents challenges in solubility and stability at the high concentrations for sunscreen formulations. To overcome these hurdles, Matsumoto Trading has dedicated research and development, pioneering an innovative technology utilizing a high concentration of ferulic acid in a solid stick formulation. This novel formulation has been developed with SPF50+ and PA++ (in vitro) containing only ferulic acid, a natural UV absorber extracted from rice bran. This unique formulation eliminates the need for other commonly used UV protective ingredients, while maintaining high sun protection effectiveness. Patent pending.

About Tsuno Rice Fine Chemicals Co., Ltd.

Tsuno Rice Fine Chemicals manufactures various ingredients from by-products generated in the process of refining rice bran oil, and they can be used for pharmaceutical, cosmetic, functional foods, food additives, feedstock, and industrial chemicals. In addition, we are also engaged in the manufacture of cosmetics under our own brand that incorporate these ingredients.

Business Profile of Tsuno Group Co., Ltd.

We are promoting the advanced and effective use of rice bran, a symbol of health and beauty that has been popular since ancient times. We are developing three businesses: the Rice Bran Oil Production Business, the Fine Chemicals Business, and the Oleo Chemical Business.

Established: February 1, 1947
Representative Director and President Fumi Tsuno
URL : https://www.tsuno.co.jp/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240130923907/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press release

Ranks 125th Among 500 Companies Around the GlobeTop 10% in the Environmental Sector Among 3,000 Major Global Companies Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 10

Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release

The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa

ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release

Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai

Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye